Page last updated: 2024-11-05

diphenyl sulfoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diphenyl sulfoxide (DPSO) is an organosulfur compound with the formula (C6H5)2SO. It is a white solid that is soluble in most organic solvents but insoluble in water. DPSO is a versatile compound with applications in various fields, including organic synthesis, material science, and pharmacology. It serves as a precursor to other sulfur-containing compounds and is employed in the production of pharmaceuticals, agrochemicals, and polymers. Research on DPSO focuses on its synthesis, reactivity, and potential biological activity. Studies have explored its use as a catalyst in organic reactions, its ability to form supramolecular assemblies, and its potential as an antioxidant and anti-inflammatory agent. Additionally, DPSO exhibits interesting properties, including fluorescence and liquid-crystalline behavior, making it a subject of investigation for the development of novel materials.'

diphenyl sulfoxide: electron acceptor for liver aldehyde oxidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13679
CHEMBL ID336123
CHEBI ID177532
SCHEMBL ID43199
SCHEMBL ID11146322
MeSH IDM0140350

Synonyms (55)

Synonym
4v290005u9 ,
4-06-00-01489 (beilstein handbook reference)
unii-4v290005u9
da9185000
benzenesulinylbenzene
CHEBI:177532
nsc-630195
945-51-7
phenyl sulfoxide
mls002637932 ,
diphenyl sulfoxide
nsc-6779
nsc6779
benzene,1'-sulfinylbis-
phenylsulfinylbenzene
sulfoxide, diphenyl
1,1'-sulfinyldibenzene
AE-848/32195054
einecs 213-415-9
nsc 6779
nsc 630195
ai3-00190
brn 1908444
diphenylsulfoxide
benzene, 1,1'-sulfinylbis-
benzenesulfinylbenzene
nsc630195
2ph-so
diphenyl sulphoxide
inchi=1/c12h10os/c13-14(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10
diphenyl sulfoxide, 96%
D1002
smr000769015
1-(phenylsulfinyl)benzene
CHEMBL336123
A845000
benzenesulfinylbenzene;sulfinyldibenzene
AKOS005258139
HMS3080B13
(phenylsulfinyl)benzene
sulfinyldibenzene
FT-0625238
pheny sulfoxide
SCHEMBL43199
SY012911
mfcd00002085
SCHEMBL11146322
W-100192
1,1'-sulfinylbis(benzene)
DTXSID0022141
CS-W015498
AS-14717
Q27260538
EN300-391768
(benzenesulfinyl)benzene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfoxideAn organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency141.25405.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency141.25405.804836.130665.1308AID540263
gemininHomo sapiens (human)Potency1.83560.004611.374133.4983AID624296
VprHuman immunodeficiency virus 1Potency63.09571.584919.626463.0957AID651644
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID310157Cleavage of DNA at 180 uM in presence of cysteine2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
DNA cleavage by photolysis of aryl sulfoxides.
AID227824Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in anaerobic conditions (N2, benzaldehyde)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID310158Cleavage of DNA at 180 uM in anaerobic condition2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
DNA cleavage by photolysis of aryl sulfoxides.
AID227809Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in aerobic conditions (air, benzaldehyde)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID227805Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in aerobic conditions (N2, NADPH)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID227803Reduction potential (SCE) determined by differential pulse polarography of the sulfoxides with rat liver S-9 fractions2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID310155Cleavage of DNA at 180 uM2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
DNA cleavage by photolysis of aryl sulfoxides.
AID343398Octanol-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID227826Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in anaerobic conditions N2)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID227810Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in aerobic conditions (air, control)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID227806Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in aerobic conditions (N2, acetaldehyde)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID227811Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in aerobic conditions (air, without cofactors)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID280385Activation of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID227808Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in aerobic conditions (air, NADPH)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID343680Hexadecane-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID227804Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in aerobic conditions (N2, 2-hydroxypyrimidine)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID227807Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in aerobic conditions (N2, menadione)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID227825Bioreduction experiment was conducted by incubation of the sulfoxides with rat liver S-9 fractions in anaerobic conditions (N2, without cofactors)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.45)18.7374
1990's3 (10.34)18.2507
2000's15 (51.72)29.6817
2010's8 (27.59)24.3611
2020's2 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.25 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index53.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]